[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Grace Therapeutics Inc (GRCE)

Grace Therapeutics Inc (GRCE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,687
  • Shares Outstanding, K 16,274
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,790 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta 0.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.53

Options Overview Details

View History
  • Implied Volatility 175.84% (-32.28%)
  • Historical Volatility 39.25%
  • IV Percentile 42%
  • IV Rank 17.10%
  • IV High 769.94% on 03/11/26
  • IV Low 53.34% on 01/26/26
  • Expected Move (DTE 6) 0.44 (20.46%)
  • Put/Call Vol Ratio 1.25
  • Today's Volume 18
  • Volume Avg (30-Day) 92
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 6,079
  • Open Int (30-Day) 5,682
  • Expected Range 1.72 to 2.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.15
  • Growth Rate Est. (year over year) +666,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.85 +16.76%
on 07/29/26
2.53 -14.56%
on 07/15/26
-0.30 (-12.20%)
since 07/14/26
3-Month
1.85 +16.76%
on 07/29/26
2.71 -20.30%
on 06/01/26
-0.03 (-1.37%)
since 05/14/26
52-Week
1.79 +20.67%
on 04/23/26
5.18 -58.30%
on 04/02/26
-0.92 (-29.87%)
since 08/14/25

Most Recent Stories

More News
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update

PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,...

GRCE : 2.16 (+4.35%)
Grace Therapeutics Announces $10 Million Private Placement

PRINCETON, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (“Grace Therapeutics” or “the Company”), a late-stage, biopharma company advancing GTx-104, a clinical-stage,...

GRCE : 2.16 (+4.35%)
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration

FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward...

GRCE : 2.16 (+4.35%)
Quarterly GDP Featured in U.S. Next Week

Monday U.S. Featured Earnings Grace Therapeutics, Inc (NASDAQ: GRCE) (Q4) EPS for loss ...

AYI : 358.43 (-0.37%)
AVAV : 192.81 (+1.78%)
MKC : 54.67 (+0.40%)
PAYX : 122.02 (-2.70%)
MU : 971.66 (+2.30%)
APOG : 42.58 (+0.02%)
TCOM : 44.98 (-0.09%)
DRI : 225.26 (+0.79%)
FDX : 334.64 (-1.39%)
GRCE : 2.16 (+4.35%)
CCL : 28.12 (-1.06%)
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update

Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined...

GRCE : 2.16 (+4.35%)
Grace: Fiscal Q4 Earnings Snapshot

Grace: Fiscal Q4 Earnings Snapshot

GRCE : 2.16 (+4.35%)
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , June 11, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics,...

GRCE : 2.16 (+4.35%)
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , June 8, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics,...

GRCE : 2.16 (+4.35%)
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics, Inc. (“Grace” or “the Company”)...

GRCE : 2.16 (+4.35%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grace Therapeutics, Inc. ("Grace" or the "Company") (NASDAQ: GRCE). Such investors are advised...

GRCE : 2.16 (+4.35%)

Business Summary

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton,...

See More

Key Turning Points

3rd Resistance Point 2.40
2nd Resistance Point 2.29
1st Resistance Point 2.23
Last Price 2.16
1st Support Level 2.06
2nd Support Level 1.95
3rd Support Level 1.89

See More

52-Week High 5.18
Fibonacci 61.8% 3.89
Fibonacci 50% 3.48
Fibonacci 38.2% 3.08
Last Price 2.16
52-Week Low 1.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.